E

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019
E
AMG 596 EGFRvIII BiTE

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019
E

The Next Wave of IO with Dr Dan Chen

We saw a number of challenges emerge with immune agonists as antibodies and now companies are experimenting with them in bispecifics - what needs to be considered to make them work? What will the next wave of IO look like?

July 9, 2019
E

What to watch out for in Bispecifics at ASCO19

A review of 7 different targets and 18 different compounds in the maturing and highly competitive bispecific niche.

May 28, 2019
E

Insights from CIMT in Mainz Part 2

Highlights (and lowlights) from Day 2 of immunotherapy presentations at CIMT 2019 in Mainz.

May 23, 2019
E

How do we improve on 1st Generation T cell bispecifics?

An upcoming small biotech focused on IO targets with their novel platform approach

January 28, 2019
E

The Yin and Yang of biomarkers in cancer research

Some examples of potentially useful biomarker inclusion in early oncology trials

January 22, 2019
E

ASH18 Highlights from Day 2

We offer 13 key highlights from day 2 of ASH18, including some surprises.

December 2, 2018
E

New Insights on BCMA BiTEs and CAR T cell therapies in Myeloma

Update on BCMA, SLAMF7 and other targets in multiple myeloma

September 11, 2018
E

Pathways to success with NK cell therapy

Will NK cell engagers have a positive impact on checkpoint therapy and other adaptive immunotherapies?

August 28, 2018
E

A different take on targeting cancer

How do we drive more T cells into the tumour? Here's one company who are looking to do just that.

May 8, 2018
E

A look at an up and coming west coast biotech

A look at the pipeline of the up and coming Seattle biotech, Alpine Immune Sciences

January 22, 2018
E

The Future of Multiple Myeloma

A look at key pipeline developments in multiple myeloma through the lens of a global expert in the field

January 2, 2018
E

Update on CD123 and other viable targets in AML

With increasing evidence that CD123 is a suboptimal target in AML, what other approaches might be more useful to consider?

October 17, 2017
E

Jumpstarting the immune system with synthetic immunity

Jumpstarting the immune system with a synthetic immunity approach - how can we do this?

August 2, 2017
E

A hidden gem at ASCO17

How can we boost the efficacy of checkpoint therapies? One way is to drive more activated T cells into the tumour.

August 1, 2017
E

A promising IO combo approach to watch out for

Overcoming resistance to monotherapy treatment with checkpoint blockade is crucial for success with IO combos. Here's one potential solution...

June 19, 2017
E
ASCO 2014 Chicago Contemplation

An up and coming area in early oncology R&D

A look at an up and coming niche in cancer research that may turn out to be useful in conjunction with checkpoint blockade

May 22, 2017
E

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016
E

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016
E

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015